Recherche Fr menu ClientConnect
5 premiers résultats de la recherche Voir tous les résultats Recherche avancée
Recherches les plus fréquentes
Pages les plus visitées
    Référence: 20180192
    Date de publication: 2 août 2018

    Promoteur – Intermédiaire Financier




    The project consists of research, development and innovation (RDI) investments related to medical technology in the areas of acute care therapies, surgical workplaces and life science during the 2018-2021 period.


    The operation targets the promoter's RDI activities for the development of new or improved products and technologies that contribute to quality enhancement and cost efficiency in healthcare and life sciences.


    Montant BEI envisagé (montant approximatif)

    EUR 180 million

    Coût total (montant approximatif)

    EUR 417 million

    Aspects environnementaux

    The investments are expected to be carried out in existing facilities, already authorised, and which would therefore not require an environmental impact assessment (EIA) under Directive 2011/92/EU. Full environmental details will be verified during the appraisal.

    Passation des marchés

    The promoter is a private company not operating in the utilities sector, and is thus not covered by EU directives on procurement.


    Signé - 20/07/2018

    Clause de non-responsabilité

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Mots-clés correspondants

    Danemark France Allemagne Suède Industrie